Evidence map›Paper›PMID 40804546›Full record

ArticleCardiovascular and interventional radiology2025

Prostatic Artery Embolization Using Ethylene Vinyl Alcohol (EVOH) Copolymer for Benign Prostatic Hyperplasia: Twelve-Month Analysis.

Jacques Sédat, Eric Fontas, Paolo Arnoffi, Giuseppe Stranieri, Frederic Colomb, Yves Chau

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05395299 (Feasibility of Prostatic Arterial Embolization With SQUID), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05395299 nacompletednot on this map

Feasibility of Prostatic Arterial Embolization With SQUID (Ethylene Vinyl Alcohol Copolymer ) in Symptomatic Patients With Benign Prostatic Hyperplasia: Monocentric Pilot Study

TypeinterventionalSponsorCentre Hospitalier Universitaire de NiceRan2022 to 2024Enrolled12ConditionsProstatic Hyperplasia, BenignArmsSQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jacques SédatService d'Interventionnel Neurologique et Général, CHU de Nice, Hôpital Pasteur 2, 30 Voie Romaine, Nice, France. jsedat@yahoo.fr.ORCID http://orcid.org/0000-0003-2312-1457
Eric FontasDRCI, CHU de Nice, Hôpital de Cimiez, 4 Avenue Reine Victoria, Grand Hôtel, BP 1179, 06003, Nice, France.
Paolo ArnoffiService d'Interventionnel Neurologique et Général, CHU de Nice, Hôpital Pasteur 2, 30 Voie Romaine, Nice, France.
Giuseppe StranieriService d'Interventionnel Neurologique et Général, CHU de Nice, Hôpital Pasteur 2, 30 Voie Romaine, Nice, France.
Frederic ColombService d'urologie, Hôpital de Grasse, Chemin de Clavary, 06130, Grasse, France.
Yves ChauService d'Interventionnel Neurologique et Général, CHU de Nice, Hôpital Pasteur 2, 30 Voie Romaine, Nice, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur goal was to evaluate the feasibility, safety, and outcomes at 12 months of prostatic artery embolization with Ethylene Vinyl Alcohol Copolymer in patients with benign prostatic hyperplasia-related lower urinary tract symptoms. MATERIALS AND

methodsThis was a single-centre prospective study from November 2023 to November 2024 registered in clinical trials (IDRCB, 2021-AO29-56-35). Twelve consecutive patients were included. Inclusion criteria were an IPSS > 18 or a QoL score > 2, and prostate volume > 40 mL. Exclusion criteria were prostate cancer, advanced atherosclerosis. Outcomes were assessed at 12 months using the International Prostate Symptoms Score and associated quality-of-life score, prostate volume, and post-void residual volume. The overall evolution was analysed using a mixed-effects model with repeated measures.

resultsBilateral injection was performed in all patients. No patients experienced major adverse events. Compared to baseline, statistically significant improvements were observed at 12 months for the IPSS (9.3 ± 7.8 vs. 17.9 ± 5.8; P = 0.03), IPSS-QoL (2.1 ± 1.9 vs. 4.8 ± 1.1; P = 0.01). No statistically significant improvements were observed at 12 months for post-void residual volume (41.5 ± 54.96 vs. 57.3 ± 61.3; P = 0.9) and prostate volume (82.7 ± 46.6 mL vs. 89.2 ± 34.1 mL; P = 0.6).

conclusionsProstatic artery embolization with Ethylene Vinyl Alcohol Copolymer is safe. This method provides good outcomes at 12 months, but no effect on the prostate volume and post-void residual volume. It deserves further evaluation in randomised trials with longer follow-up.

trial registrationThis study was performed according to Good Clinical Practice requirements and the Helsinki Declaration and registered on Clinical Trials.gov (Trial registration: IDRCB, 2021-AO29-56-35. Registered 27 May 2022, http://clinicaltrials.gov/study/NCT05395299?cond=embolization&term&rank=1 ).

Indexed as

Embolization, TherapeuticLower Urinary Tract SymptomsPolyvinylsProstateProstatic HyperplasiaAgedFeasibility StudiesHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment Outcomeethylene-vinyl alcohol copolymerPolyvinylsBenign prostate hyperplasiaEthylene vinyl alcohol copolymerLower urinary tract symptomsProstate artery embolization

Identifiers

PMID40804546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.